ДоземірClinical dose reference · modeled pharmacokinetics
ENUA
Split / crush

Can this pill be split or crushed?

Look up whether a tablet may be split, crushed, or dispersed for a feeding tube. Answers are modeled from the product's formulation and curated label sources — always confirm against the registered product information (інструкція) and a pharmacist.

Pick a product

Start with a known product for an instant answer.

Shown as an example — not a recommendation for any patient.

Modeled verdict

Product: Telmista Trio 80/10/12.5 mg (telmisartan + amlodipine + HCTZ)

  • Split / divide: No

    Multilayer fixed-dose combination tablet: splitting cannot give a uniform fraction and destroys the coating or release matrix — do not split.

    Evidence: Tier B — Reasonable method with moderate or indirect supporting evidence.Verified as of 2026-06-02
    Source
    • КРКА, д.д., Ново место (KRKA, d.d.) (2025) (opens in a new tab) ТЕЛМІСТА® ТРІО (телмісартан / амлодипін / гідрохлоротіазид) — інструкція для медичного застосування. інструкція для медичного застосування (Держреєстр ЛЗ). Identifier: UA/20961/01/01
      Verbatim from the source:
      овальні, двоопуклі, двошарові таблетки

  • Crush: No

    Multilayer fixed-dose combination tablet: crushing causes loss of coating protection, dose dumping, or non-uniform delivery — do not crush.

    Evidence: Tier B — Reasonable method with moderate or indirect supporting evidence.Verified as of 2026-06-02
    Source
    • КРКА, д.д., Ново место (KRKA, d.d.) (2025) (opens in a new tab) ТЕЛМІСТА® ТРІО (телмісартан / амлодипін / гідрохлоротіазид) — інструкція для медичного застосування. інструкція для медичного застосування (Держреєстр ЛЗ). Identifier: UA/20961/01/01
      Verbatim from the source:
      овальні, двоопуклі, двошарові таблетки

  • Disperse for a feeding tube: No

    Multilayer fixed-dose combination tablet: dispersing for a feeding tube defeats the coating or release matrix exactly as crushing does — do not disperse.

    Evidence: Tier B — Reasonable method with moderate or indirect supporting evidence.Verified as of 2026-06-02
    Source
    • КРКА, д.д., Ново место (KRKA, d.d.) (2025) (opens in a new tab) ТЕЛМІСТА® ТРІО (телмісартан / амлодипін / гідрохлоротіазид) — інструкція для медичного застосування. інструкція для медичного застосування (Держреєстр ЛЗ). Identifier: UA/20961/01/01
      Verbatim from the source:
      овальні, двоопуклі, двошарові таблетки

If manipulated: Manipulation breaks the layered structure and gives non-uniform delivery of the co-formulated actives.

Why crushing matters (modeled illustration)

Modeled illustration

This is the documented verapamil case (crushed 24-hour exposure about 1.7× the intact tablet; Kumagai 2024), shown as an example of why modified-release products must not be crushed. It is NOT a prediction for the product you are viewing.

Intact (modified-release) — smoothCrushed — early spike
00.20.40.60.8104812162024Time (hours)Modeled concentration (mg/L)
Modeled concentration over 24 hours: the crushed profile rises to an early spike while the intact modified-release profile stays smooth and low. Crushed 24-hour exposure is about 1.7× the intact tablet (verapamil, Kumagai 2024).

Modeled 24-hour exposure: crushed ≈ 1.7× intact.

Evidence: Tier A — Well-validated method backed by primary clinical evidence.
Source
  • Kumagai S, et al. (2024) (opens in a new tab) Comparative analysis of verapamil pharmacokinetics: simple suspension and crushing. J Clin Med. Identifier: Consensus record 035221cda10f5a5f9ce549d3e142d945
    Verbatim from the source:
    the area under the curve for verapamil during the initial 24 h period was 1.7 and 1.3 times greater in the crushed and simple suspension groups, respectively, than in the tablet group.
Educational PK model — not clinical guidance. Confirm any dose change with a prescriber or pharmacist.